2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1100

A Functional Growth Hormone Receptor Polymorphism, Exon 3 Deleted Ghr, Is Associated with Radiographic Knee Osteoarthritis in Females with Familial Osteoarthritis At Multiple Sites: The Garp Study
Abstract Number: 1760

A Gene Expression Signature to Monitor Depletion of Plasma Cells Following MEDI-551 (anti-CD19) Administration
Abstract Number: 2323

A Genetic Polymorphism on New Zealand Black Chromosome 1 Is Associated with Abnormal Dendritic Cell Function Leading to Expansion of T_H1, T_H17 and T Follicular Helper (T_FH) Cells
Abstract Number: 2671

A Genome-Wide Association Study Establishes Muliple Susceptibility Loci for Sjögren’s Syndrome
Abstract Number: 993

A Genome-Wide DNA Methylation Analysis Reveals Different Methylation Patterns in the OA Disease
Abstract Number: 2370

A Genome-Wide DNA Methylation Study Identifies Significant Epigenetic Changes Across the Genome and in Multiple HLA Loci in Behcet’s Disease
Abstract Number: 978

A Genome-Wide Interaction Study with Smoking Suggests New Risk Loci for Two Different Subsets of Rheumatoid Arthritis; Results From Swedish Epidemiological Investigation of Rheumatoid Arthritis Study
Abstract Number: 595

A Genomewide Association Study of Anterior Uveiti
Abstract Number: 2666

A Link Between B Cells and Bone Erosion in RA: RANKL Production by Memory B Cells
Abstract Number: 2140

A Longitudinal Study of Prognostic Factors in Patients with Early RA Providing Direction for Future Clinical Treatment- Predict Study
Abstract Number: 865

A Methodology for Estimating Disease State Transitions: Repeated Measures Markov Models with Covariate Dependence
Abstract Number: 30

A Mouse Myeloid Precursor with Osteoclastogenic Function in Vivo
Abstract Number: 2121

A Multi-Biomarker Disease Activity (VECTRA™ DA Algorithm) Score Reflects Clinical Disease Activity and Structural Changes in Rheumatoid Arthritis Patients Treated with Tocilizumab
Abstract Number: 2664

A Multi-Biomarker Disease Activity (VECTRA™ DA Algorithm) Score Reflects Clinical Disease Activity and Tracks Responses in Patients with Rheumatoid Arthritis Treated with Either Adalimumab, Etanercept, and Infliximab
Abstract Number: 2700

A Multi-Center Study of the Appropriateness of Anti-Neutrophilic Cytoplasmic Antibody Testing

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].